Peripheral blood mononuclear cell transcriptome profile in a clinical trial with subcutaneous, grass pollen allergoid immunotherapy

Citations Over TimeTop 15% of 2024 papers

Abstract

Abstract Introduction Allergen‐specific immunotherapy (AIT) is the only disease‐modifying treatment in allergic airway diseases. Underlying immunological mechanisms and candidate biomarkers, which may be translated into predictive/surrogate measures of clinical efficacy, remain an active area of research. The aim of this study was to evaluate Pollinex Quattro (PQ) Grass AIT induced immunomodulatory mechanisms, based on transcriptome profiling of peripheral blood mononuclear cells. Methods 119 subjects with grass pollen induced seasonal allergic rhinitis (SAR) were randomized in a 2:2:1:1 ratio to receive a cumulative dose of PQ Grass as a conventional or extended pre‐seasonal regimen, placebo, or placebo with MicroCrystalline Tyrosine. Gene expression analysis was an exploratory endpoint evaluated in a subgroup of 30 subjects randomly selected from the four treatment arms. Samples were collected at three time points: screening (baseline), before the start of the grass pollen season and at the end of the season. This study was funded by the manufacturer of PQ. Results Transcriptome analysis demonstrated that the most significant changes in gene expression, for both treatment regimens, were at the end of the grass pollen season, with the main Th1 candidate molecules (IL‐12A, IFNγ) upregulated and Th2 signature cytokines downregulated (IL‐4, IL‐13, IL‐9) ( p < .05). Canonical pathways analysis demonstrated Th1, Th2, Th17 and IL‐17 as the most significantly enriched pathways based on absolute value of activation z ‐score (I z I score ≥ 2, p < .05). Upstream regulator analysis showed pronounced inhibition of pro‐inflammatory allergic molecules IgE, IL‐17A, IL‐17F, IL‐25 (IL‐17E) (I z I score ≥ 2, FDR < 0.05) and activation of pro‐tolerogenic molecules IL‐12A, IL‐27, IL‐35 (EBI3) at the end of the grass pollen season. Conclusion Peripheral blood mononuclear cells transcriptome profile showed an inhibition of Th2, Th17 pro‐inflammatory allergic responses and immune deviation towards Th1 responses. PQ Grass extended regimen exhibited a superior mechanistic efficacy profile in comparison with PQ conventional regimen.

Related Papers

• → A Review of Secukinumab in Psoriasis Treatment(2020)22 cited
• → Investigation of plaque psoriasis relapse after secukinumab withdrawal in patients from two phase III studies(2023)16 cited
• → Secukinumab (AIN-457) for the treatment of Psoriasis(2015)13 cited
• → Management of Moderate and Severe Forms of Psoriasis in Children: New Opportunities of Genetically Engineered Biologic Drugs(2021)4 cited
• → AB0639 TREATMENT EFFICACY WITH SECUKINUMAB IN A COHORT OF SPONDYLOARTHRITIS PATIENTS(2020)